Dendritic cells (DCs) are highly specialized antigen-presenting cells endowed with the unique ability to not only present exogenous
antigens upon exposure to MHC II, but also to cross-present these upon exposure to MHC I. This property was exploited to generate the
tumor-specific CD8 cytotoxic lymphocyte (CTL) response in DCs-based
cancer vaccine protocols. In this context, the source of
tumor antigens remains a critical challenge. A crude
tumor in the context of danger signals is believed to represent an efficient source of
tumor antigens (TAs) for DCs loading. In our previous work, increased DCs cross-presentation of
antigens from necrotic gastric
carcinoma cells paralleled up-regulation of the
heat shock protein hsp70. We studied the expression of hsp70 on primary colon
carcinoma cells and its relevance in the cross-priming of anti-
tumor CTL by
tumor-loaded DCs. Hsp70 was expressed on all three of the
tumors studied, but was never detected in the peritumoral normal mucosa (NM). The uptake of the
tumor induced a trend towards down-modulation of the monocyte-specific marker CD14, but had no effect on the
chemokine receptors CCR4 and CCR7. The IFN-gamma
enzyme-linked immunospot assay (ELIspot) showed cross-priming of CTL by
tumor-loaded but not NM-loaded DCs in four of the six cases studied. The CTL response generated in DC+tumor cultures was directed towards the
tumor, but not towards NM, and it was characterized by refractoriness to polyclonal (Ca
ionophores, PKC activators) stimuli. Of the three CTL-generating
tumors, only one expressed hsp70. This data indicates a
tumor-specific expression of hsp70, but does not support its relevance in the DC cross-presentation of TAs.